Search News Archives
Follow us on
Conferences | Events
Media Partners

Cell-line Derived Controls for Diagnostic Assay Development

publication date: Nov 2, 2017
 | 
author/source: AMSBIO

Cell

AMSBIO announce the addition of mutation cell line Formalin-Fixed Paraffin-Embedded (FFPE) samples and isolated genomic DNA (gDNA) controls to its extensive range of cell line reference standards.

In both routine clinical use and diagnostic assay development, biologically-relevant positive and negative controls represent an invaluable resource. To ensure accuracy and reproducibility during IVD assay development and established diagnostic tests, reference standards for genomic DNA analysis and Immunohistochemistry (IHC) assays are an essential tool. However reliable sources of reference material for rarer genetic profiles remain a constant challenge.

IsoMax™ reference standards have been accurately engineered to model the genetics of specific patient populations in vitro. These unique new reference standards can be directly incorporated into sample processing workflows for assay optimization, evaluation of sensitivity and specificity as well as monitoring the impact of workflow changes on downstream analysis.

Building on the CellMax™ range of more than 50 well-known cancer cell line FFPE controls, IsoMax™ reference standards provide a renewable source of control material for recognized mutations in cancer markers.  Based on CRISPR/Cas9 isogenic cell lines, a wide range of mutations are offered from target genes, including EGFR, KRAS, BRAF, and PIK3CA.

Available in multiple formats, including FFPE blocks, slides, scrolls, and isolate gDNA, IsoMax™ and CellMax™ standards provide an inexhaustible supply of consistent positive and negative controls.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.


more about AMSBIO


more news from AMSBIO


 

 

 


If you have not logged into the website then please enter your details below.



 

Popular this month


 

Lose the Solvent Headache with Cole-Parmer VapLock™ Closed Systems


Tomocube adds 3D Fluorescence Imaging to Holotomography Microscopy for World First


ZEISS Elyra 7 with Lattice SIM IntroducedZEISS Elyra 7 with Lattice SIM Introduced


Restek Now Has Even More of What You Need to Keep Your LC Flowing


Metrohm contributes to global monograph modernization initiative


Fused-Core Selectivity Toolkits for Superficially-Porous Particle Method Development


Introducing Renishaw’s New RA816 Biological Analyser


ID Kit – fast, easy, and accurate detection of heroin and other illicit drugs


Safe Evaporative Sample Preparation of High Potency APIs


Simplifying high content screening with the VIAFLO 96

 

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd
Media Partners